<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sargramostim: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sargramostim: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sargramostim: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9878" href="/d/html/9878.html" rel="external">see "Sargramostim: Drug information"</a> and <a class="drug drug_patient" data-topicid="11445" href="/d/html/11445.html" rel="external">see "Sargramostim: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F220032"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Leukine</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1049810"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Colony-Stimulating Factor</span>;</li>
<li>
<span class="list-set-name">Hematopoietic Agent</span></li></ul></div>
<div class="block don drugH1Div" id="F53462582"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2b023352-e996-45ca-bc73-7b80e79209bd">Neutropenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neutropenia:</b> Limited data available; efficacy result variable: SubQ: 10 mcg/<b>kg</b>/dose once daily for 5 days. The PROGRAMS trial (single-blind, multicenter) evaluated use in 280 premature neonates (GA: ≤31 weeks; weight: ≤10th percentile body weight) and showed a correction of neutropenia but no reduction in sepsis or improved survival (Carr 2009); an extension study also reported no difference in developmental, neurological, or general health outcomes in former premature neonates who received sargramostim compared to placebo (Marlow 2013)</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F46193210"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27bcee32-c0a9-416e-b251-a721fc52f9aa">Neutrophil recovery; myeloid reconstitution</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neutrophil recovery; myeloid reconstitution:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Allogeneic bone marrow transplantation:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥5 months and Children &lt;2 years: Limited data available: IV: 250 mcg/m<sup>2</sup>/day infused over 4 hours once daily; begin on day 0 of the BMT and administer first dose after marrow infusion completed and continue for 21 days; discontinue if ANC &gt;20,000/mm<sup>3</sup> (Trigg 2000)</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥2 years and Adolescents: IV: 250 mcg/m<sup>2</sup>/day infused over 2 hours; begin 2 to 4 hours after the marrow infusion and at least 24 hours after chemotherapy or radiotherapy; do not initiate until the post marrow infusion ANC is &lt;500/mm<sup>3</sup> and continue until ANC &gt;1,500/mm<sup>3</sup> for 3 consecutive days</p>
<p style="text-indent:-2em;margin-left:8em;">If WBC &gt;50,000/mm<sup>3</sup> or ANC &gt;20,000/mm<sup>3</sup>, interrupt treatment or reduce the dose by 50%.</p>
<p style="text-indent:-2em;margin-left:8em;">If grade 3 or 4 adverse reactions occur, reduce dose by 50% or temporarily discontinue the dose until the reaction abates.</p>
<p style="text-indent:-2em;margin-left:8em;">If blast cells appear or progression of the underlying disease occurs, discontinue treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Autologous bone marrow transplantation</i>:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥2 years and Adolescents: IV: 250 mcg/m<sup>2</sup>/day infused over 2 hours; begin 2 to 4 hours after the marrow infusion and at least 24 hours after chemotherapy or radiotherapy; do not initiate until the post marrow infusion ANC is &lt;500/mm<sup>3</sup> and continue until ANC &gt;1,500/mm<sup>3</sup> for 3 consecutive days. Do not administer within 24 hours before or after chemotherapy or radiation therapy.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0c65ada8-8aef-4317-aa0a-7171c525a86c">Delayed neutrophil recovery or graft failure; allogeneic or autologous bone marrow transplantation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Delayed neutrophil recovery or graft failure; allogeneic or autologous bone marrow transplantation: </b>Children ≥2 years and Adolescents: IV: 250 mcg/m<sup>2</sup>/day infused over 2 hours for 14 days; may repeat 14-day course if engraftment has not occurred after 7 days off sargramostim. If neutrophil recovery still has not occurred after 7 days off sargramostim, a third course of 500 mcg/m<sup>2</sup>/day for 14 days may be attempted. If there is still no improvement, it is unlikely that further dose escalation will be of benefit.</p>
<p style="text-indent:-2em;margin-left:4em;">If WBC &gt;50,000/mm<sup>3</sup> or ANC &gt;20,000/mm<sup>3</sup>, interrupt treatment or reduce the dose by 50%.</p>
<p style="text-indent:-2em;margin-left:4em;">If grade 3 or 4 adverse reactions occur, reduce the dose by 50% or temporarily discontinue the dose until the reaction abates.</p>
<p style="text-indent:-2em;margin-left:4em;">If blast cells appear or disease progression occurs, discontinue treatment immediately.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c2c274db-ea5a-48a8-95b4-74a2e455133e">Hematopoietic radiation injury syndrome, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoietic radiation injury syndrome, acute:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight-directed dosing: </i>Infants, Children, and Adolescents: Begin as soon as possible after suspected or confirmed exposure to radiation doses &gt;2 gray (Gy); do not delay sargramostim if CBC is not readily available; continue sargramostim until ANC remains &gt;1,000/mm<sup>3</sup> for 3 consecutive CBCs (obtain CBCs approximately every 3 days) or ANC exceeds 10,000/mm<sup>3</sup> after radiation-induced nadir.</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;15 kg: SubQ: 12 mcg/<b>kg</b> once daily</p>
<p style="text-indent:-2em;margin-left:6em;">15 to 40 kg: SubQ: 10 mcg/<b>kg</b> once daily</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;40 kg: SubQ: 7 mcg/<b>kg</b> once daily</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>BSA-directed dosing: </i>Limited data available: Children and Adolescents: SubQ: 250 mcg/m<sup>2</sup>/day; continue until ANC &gt;1,000/mm<sup>3</sup> (Waselenko 2004). <b>Note</b>: ASCO guidelines recommend initiating within 24 hours of exposure of a dose ≥2 Gy and/or significant decrease in absolute lymphocyte count, or for anticipated neutropenia &lt;500/mm<sup>3</sup> for ≥7 days (ASCO [Smith 2015]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9620891e-d91b-4073-80a0-b2f9c15bd320">Neuroblastoma, high-risk</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroblastoma, high-risk:</b> Limited data available: Infants, Children, and Adolescents: SubQ or IV: 250 mcg/m<sup>2</sup> once daily for 14 days during cycles 1, 3, and 5, beginning 3 days prior to administration of dinutuximab (each cycle is 28 days) as part of a multi-drug regimen that includes dinutuximab, isotretinoin, and aldesleukin (Gilman 2009; Yu 2010).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51192787"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51192788"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F220035"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9878" href="/d/html/9878.html" rel="external">see "Sargramostim: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> May round the dose to the nearest vial size (ASCO [Ozer 2000]).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="32918b6e-21b5-4cfb-9970-4e632f1618c7">Acute myeloid leukemia, following induction chemotherapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute myeloid leukemia, following induction chemotherapy:</b> Adults ≥55 years: <b>IV:</b> 250 mcg/m<sup>2</sup>/day (infused over 4 hours) starting approximately on day 11 or 4 days following the completion of induction chemotherapy (if day 10 bone marrow is hypoplastic with &lt;5% blasts), continue until ANC &gt;1,500/mm<sup>3</sup> for 3 consecutive days or a maximum of 42 days. Do not administer within 24 hours before or after chemotherapy or radiation therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">If a second cycle of chemotherapy is necessary, administer ~4 days after the completion of chemotherapy if the bone marrow is hypoplastic with &lt;5% blasts.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7bc3fabd-0ae7-441c-b467-28ebb74e1934">Allogeneic bone marrow transplantation, myeloid reconstitution</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allogeneic bone marrow transplantation, myeloid reconstitution: IV:</b> 250 mcg/m<sup>2</sup>/day (infused over 2 hours), begin 2 to 4 hours after the bone marrow infusion and at least 24 hours after chemotherapy or radiotherapy, do not initiate until the post marrow infusion ANC is &lt;500/mm<sup>3</sup>, and continue until ANC &gt;1,500/mm<sup>3</sup> for 3 consecutive days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4e0c8103-8fb5-4245-9271-6fe332d59c78">Allogeneic or autologous bone marrow transplantation, treatment of delayed neutrophil recovery or graft failure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allogeneic or autologous bone marrow transplantation, treatment of delayed neutrophil recovery or graft failure:</b>
<b>IV:</b> 250 mcg/m<sup>2</sup>/day (infused over 2 hours) for 14 days; If engraftment has not occurred after 7 days off sargramostim, may repeat. If neutrophil recovery still has not occurred after 7 days off sargramostim, a third course of 500 mcg/m<sup>2</sup>/day for 14 days may be attempted. If there is still no improvement, it is unlikely that further dose escalation will be of benefit.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="758f6034-96ca-4ca1-b27e-8df712612641">Autologous peripheral blood progenitor cell mobilization and collection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Autologous peripheral blood progenitor cell mobilization and collection: IV, SUBQ:</b> 250 mcg/m<sup>2</sup>/day IV (infused over 24 hours) or SUBQ once daily; continue the same dose throughout peripheral blood progenitor cell collection period.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> The optimal schedule for peripheral blood progenitor cell collection has not been established (usually begun 5 days after sargramostim and performed daily until protocol specified targets are achieved). If adequate numbers of progenitor cells are not collected, consider other mobilization therapy.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9fafb639-a1b2-4886-81cf-e7f3f49c72f1">Autologous peripheral blood progenitor cell transplantation, myeloid reconstitution</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Autologous peripheral blood progenitor cell transplantation, myeloid reconstitution: </b>
<b>IV, SUBQ:</b> 250 mcg/m<sup>2</sup>/day IV (infused over 24 hours) or SUBQ once daily beginning immediately following infusion of progenitor cells; continue until ANC is &gt;1,500/mm<sup>3</sup> for 3 consecutive days. Do not administer within 24 hours before or after chemotherapy or radiation therapy.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="09b99839-0112-4c17-bf75-5cccc3a4d415">Autologous bone marrow transplantation, myeloid reconstitution</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Autologous bone marrow transplantation, myeloid reconstitution: IV:</b> 250 mcg/m<sup>2</sup>/day (infused over 2 hours), begin 2 to 4 hours after the bone marrow infusion and at least 24 hours after chemotherapy or radiotherapy, do not initiate until the post marrow infusion ANC is &lt;500/mm<sup>3</sup>, and continue until ANC &gt;1,500/mm<sup>3</sup> for 3 consecutive days. Do not administer within 24 hours before or after chemotherapy or radiation therapy.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c2c274db-ea5a-48a8-95b4-74a2e455133e">Hematopoietic radiation injury syndrome, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoietic radiation injury syndrome, acute: SUBQ:</b> Adults &gt;40 kg: 7 mcg/kg once daily; begin as soon as possible after suspected or confirmed exposure to radiation doses &gt;2 (gray) Gy; do not delay sargramostim if CBC is not readily available; continue sargramostim until ANC remains &gt;1,000/mm<sup>3</sup> for 3 consecutive CBCs (obtain CBCs approximately every 3 days) or ANC exceeds 10,000/mm<sup>3</sup> after radiation-induced nadir.</p>
<p style="text-indent:0em;margin-left:2em;">
<i>Off-label dosing: </i>
<b>SUBQ:</b> 250 mcg/m<sup>2</sup>/day; continue until ANC &gt;1,000/mm<sup>3</sup> (Waselenko 2004). ASCO guidelines recommend initiating within 24 hours of exposure of a dose ≥2 Gy and/or significant decrease in absolute lymphocyte count, or for anticipated neutropenia &lt;500/mm<sup>3</sup> for ≥7 days (ASCO [Smith 2015]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a24e5302-cc1a-4b3b-a726-8b9596fb0013">Neuroblastoma, high risk, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroblastoma, high risk, relapsed or refractory (off-label use): SUBQ:</b> 250 mcg/m<sup>2</sup>/day for 5 days on days −4 to 0, followed by 500 mcg/m<sup>2</sup>/day for 5 days on days 1 to 5 of each 4-week treatment cycle (in combination with naxitamab; on naxitamab days, administer sargramostim at least 1 hour prior to naxitamab) (Danyelza product labeling; Kushner 2019). <b>Note:</b> Treatment cycles are repeated every 4 weeks until complete or partial response, followed by 5 additional cycles (every 4 weeks). Subsequent cycles may be repeated every 8 weeks. Discontinue (naxitamab and GM-CSF) with disease progression or unacceptable toxicity. Refer to Naxitamab monograph for naxitamab dosing and premedication/pain management recommendations.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1c877bb0-1166-4f44-ac2c-38ac368b4a61">Primary prophylaxis of neutropenia in patients receiving chemotherapy or who are at high risk for neutropenic fever</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary prophylaxis of neutropenia in patients receiving chemotherapy (outside transplant and AML) or who are at high risk for neutropenic fever (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>
<b>:</b> WBC growth factors are generally recommended to reduce the risk of neutropenic fever when the anticipated risk of neutropenic fever for a chemotherapy regimen is approximately ≥20% (ASCO [Smith 2015]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> 250 mcg/m<sup>2</sup>/day beginning at least 24 hours after chemotherapy administration; continue until ANC &gt;1,500/mm<sup>3</sup> for 3 consecutive days (ASCO [Smith 2015]).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50992040"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50989275"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F220003"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (34%), edema (13% to 25%), pericardial effusion (4% to 25%), chest pain (15%), peripheral edema (11%), tachycardia (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Malaise (57%), headache (26%), chills (25%), anxiety (11%), insomnia (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin changes (77%), skin rash (44%), pruritus (23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Elevated serum glucose (49%), weight loss (37%), decreased serum albumin (36%), hyperglycemia (25%), hypomagnesemia (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (81% to 89%), nausea (58% to 70%), vomiting (46% to 70%), abdominal pain (38%), anorexia (13%), hematemesis (13%), dysphagia (11%), gastrointestinal hemorrhage (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hyperbilirubinemia (30%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (66%), ostealgia (21%), arthralgia (11% to 21%), myalgia (18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Retinal hemorrhage (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pharyngitis (23%), epistaxis (17%), dyspnea (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (81%), laboratory test abnormality (58%, metabolic)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pleural effusion (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, bone marrow dysplasia, capillary leak syndrome, cardiac disease, decreased serum total protein, eosinophilia, erythema, flushing, hemorrhage (neurocortical events), hypersensitivity reaction, hypotension, hypoxia, increased monocytes, infusion related reaction, injection site reaction, leukocytosis, liver function impairment, pain, prolonged prothrombin time, respiratory distress, supraventricular cardiac arrhythmia, syncope, thromboembolic complications, urticaria, weight gain</p></div>
<div class="block coi drugH1Div" id="F220018"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">History of serious allergic reactions, including anaphylaxis, to human granulocyte-macrophage colony stimulating factor such as sargramostim, yeast-derived products, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F220000"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular effects: Supraventricular arrhythmia has been reported during sargramostim administration, particularly in patients with a prior history of cardiac arrhythmia. These arrhythmias have been reversible following sargramostim discontinuation. Use with caution in patients with preexisting cardiac disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Effusions/capillary leak syndrome: Edema, capillary leak syndrome, pleural and/or pericardial effusion have been reported. Sargramostim may aggravate fluid retention in patients with preexisting pleural and pericardial effusions; however, fluid retention has been shown to be reversible with dosage reduction or discontinuation of sargramostim with or without concomitant use of diuretics. Use with caution in patients with preexisting fluid retention, pulmonary infiltrates, or congestive heart failure.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Serious allergic and anaphylactic reactions have been reported; use appropriate precautions with parenteral administration of sargramostim in the event of allergic reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunogenicity: Treatment with sargramostim may induce neutralizing anti-drug antibodies. Antibody formation may be related to duration of sargramostim exposure; use sargramostim for the shortest duration necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion reactions: IV administration of sargramostim may be associated with infusion-related reactions; symptoms may include respiratory distress, hypoxia, flushing, hypotension, syncope, and/or tachycardia following the initial IV infusion in a cycle. Infusion reactions have resolved with symptomatic treatment and generally do not recur with subsequent doses within the same treatment cycle. Observe closely for symptoms during infusion, particularly in patients with preexisting pulmonary disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Leukocytosis: White blood cell counts ≥50,000/mm<sup>3</sup> have observed with sargramostim. The decision to reduce the dose or interrupt treatment should be based on the patient's clinical condition. Following cessation of therapy, excessive blood counts return to normal or baseline levels within 3 to 7 days.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cytotoxic chemotherapy/radiotherapy: Do not administer simultaneously with or within 24 hours preceding/following cytotoxic chemotherapy or radiotherapy (due to the sensitivity of rapidly dividing hematopoietic progenitor cells).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric patients: Colony-stimulating factor (CSF) use in pediatric patients is typically directed by clinical pediatric protocols. The ASCO Recommendations for the Use of WBC Growth Factors Clinical Practice Guideline Update states that CSFs may be reasonable as primary prophylaxis in pediatric patients when chemotherapy regimens with a high likelihood of febrile neutropenia are employed. Likewise, secondary CSF prophylaxis should be limited to high-risk patients. In pediatric cancers in which dose-intense chemotherapy (with a survival benefit) is used, CSFs should be given to facilitate chemotherapy administration. CSFs should not be used in the pediatric population for non-relapsed acute lymphoblastic or myeloid leukemia when no infection is present (ASCO [Smith 2015]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms or diluents may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Tumor growth factor: May potentially act as a growth factor for any tumor type, particularly myeloid malignancies; caution should be exercised when using in any malignancy with myeloid characteristics.</p></div>
<div class="block foc drugH1Div" id="F220011"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Leukine: 250 mcg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F219996"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323819"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Leukine Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mcg (per each): $370.15</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52613841"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">IV: Administer as 2-hour,  4-hour, or 24-hour infusion (indication specific). An in-line membrane filter should <b>not</b> be used for intravenous administration. Do not shake solution to avoid foaming. </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">SubQ: Administer reconstituted solution without further dilution; rotate injection sites; avoiding navel/waistline  </p></div>
<div class="block adm drugH1Div" id="F220015"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Sargramostim is administered as a SUBQ injection or IV infusion. Administer at approximately the same time each day.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse over 2 hours, 4 hours or 24 hours (indication specific). An in-line membrane filter should <b>NOT</b> be used for intravenous administration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> Administer subcutaneously into the thigh, abdomen (avoiding waistline and avoiding within 2 inches of navel), or (if a caregiver administers) the outer upper arm; rotate injection sites (injection sites should be at least 1 inch apart from prior injection sites). Do not inject into areas that are tender, bruised, red, or hard; avoid areas with scars or stretch marks. Administer without further dilution.</p></div>
<div class="block sts drugH1Div" id="F220028"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;display:inline">Store intact vials at 2°C to 8°C (36°F to 46°F); do not freeze. Store in the original carton to protect from light. Do not shake.</p>
<p style="text-indent:-2em;margin-left:2em;">Powder for injection: Vials reconstituted with preservative-free SWFI may be stored at 2°C to 8°C (36°F to 46°F) for up to 24 hours and vials reconstituted with bacteriostatic water for injection may be stored at 2°C to 8°C (36°F to 46°F) for up to 20 days. Solutions diluted for infusion must be used immediately. The contents of vials reconstituted with different diluents should not be mixed together.</p></div>
<div class="block usep drugH1Div" id="F53568785"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">To increase survival due to acute exposure to myelosuppressive radiation doses (hematopoietic syndrome of acute radiation syndrome [H-ARS]) (FDA approved in all ages); to accelerate myeloid recovery in patients undergoing autologous or allogeneic BMT and accelerates myeloid recovery following autologous peripheral stem cell transplantation and prolong survival in patients with graft failure or engraftment delay after BMT (FDA approved in ages ≥2 years and adults); mobilizes hematopoietic progenitor cells into peripheral blood for collection by leukapheresis (FDA approved in adults); shortens time to neutrophil recovery and reduces the incidence of severe and life-threatening infections and infections resulting in death following induction chemotherapy in older adults with acute myelogenous leukemia (AML) (FDA approved in adults ≥55 years of age). Has also been used to increase neutrophil counts in patients with malignancies receiving myelosuppressive chemotherapy (beginning &gt;24 hours after chemotherapy) and for management of neonatal neutropenia; and used in combination with anti-GD2 therapy for neuroblastoma to augment the antibody-dependent cell-mediated cytotoxicity (ADCC).</p></div>
<div class="block mst drugH1Div" id="F220065"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Leukine may be confused with Leukeran, leucovorin</p>
<p style="text-indent:-2em;margin-left:4em;">Sargramostim may be confused with efbemalenograstim alfa, eflapegrastim, filgrastim, pegfilgrastim, tbo-filgrastim</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300028"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6222861"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Androgens: Hypertension-Associated Agents may enhance the hypertensive effect of Androgens. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belotecan: Granulocyte Colony-Stimulating Factors may enhance the neutropenic effect of Belotecan.  Management: Do not administer granulocyte colony-stimulating factor (G-CSF) until at least 24 hours after completion of belotecan administration. Monitor neutrophil counts and signs/symptoms of neutropenic fever in patients receiving this combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betibeglogene Autotemcel: Granulocyte Colony-Stimulating Factors may interact via an unknown mechanism with Betibeglogene Autotemcel.  Management: Granulocyte-colony stimulating factor is not recommended for 21 days after betibeglogene autotemcel infusion.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bleomycin: Granulocyte Colony-Stimulating Factors may enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased.  Management: Avoid use of granulocyte colony-stimulating factors 24 hours before (14 days for pegfilgrastim) and 24 hours after the last dose of bleomycin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the therapeutic effect of Sargramostim. Specifically, corticosteroids may enhance the myeloproliferative effects of sargramostim.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloPHOSphamide: May enhance the adverse/toxic effect of Sargramostim. Specifically, the risk of pulmonary toxicity may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Exagamglogene Autotemcel: Granulocyte Colony-Stimulating Factors may enhance the adverse/toxic effect of Exagamglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Sargramostim may enhance the adverse/toxic effect of Lithium. Specifically, the myeloproliferative effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovotibeglogene Autotemcel: Granulocyte Colony-Stimulating Factors may enhance the adverse/toxic effect of Lovotibeglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: May enhance the hypertensive effect of Hypertension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tisagenlecleucel: Granulocyte Colony-Stimulating Factors may enhance the adverse/toxic effect of Tisagenlecleucel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topotecan: Granulocyte Colony-Stimulating Factors may enhance the adverse/toxic effect of Topotecan. Specifically, the risk for the development of interstitial lung disease may be increased. Granulocyte Colony-Stimulating Factors may enhance the myelosuppressive effect of Topotecan.  Management: Avoid use of granulocyte colony-stimulating factors 24 hours before (14 days for pegfilgrastim) and 24 hours after the last dose of topotecan. Additionally, monitor patients closely for the development of interstitial lung disease with this combination.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F220021"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Data regarding use in pregnant patients is limited. Some dosage forms may contain benzyl alcohol (avoid in pregnant patients due to association with gasping syndrome in premature infants); if use is necessary during pregnancy, lyophilized powder reconstituted with preservative-free sterile water for injection is recommended.</p></div>
<div class="block mopp drugH1Div" id="F53568783"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC with differential (at least twice weekly during therapy); when monitoring for hematopoietic radiation injury syndrome, obtain CBCs approximately every 3 days; platelets; renal and hepatic function tests; vital signs, weight; hydration status; pulmonary function; monitor for signs/symptoms of hypersensitivity or infusion-related reactions.</p></div>
<div class="block pha drugH1Div" id="F219999"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Sargramostim is a colony stimulating growth factor which stimulates proliferation, differentiation, and functional activity of neutrophils, eosinophils, monocytes, and macrophages.</p></div>
<div class="block phk drugH1Div" id="F220017"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Increase in WBC in 7 to 14 days</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: WBCs return to baseline within 1 to 2 weeks of discontinuing drug</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: IV: 96.8 L</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: SubQ: 75% (compared to IV)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 months to 15 years: IV: Median: 1.6 hours; range: 0.9 to 2.5 hours; SubQ: Median: 2.3 hours (0.3 to 3.8 hours) (Stute 1995)</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: IV: 3.84 hours; SubQ: 1.4 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: IV: During or immediately after infusion; SubQ: 2.5 to 4 hours</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038802"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Emgrast M</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Leucogen</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Leukine</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sargramostim-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19150703">
<a name="19150703"></a>Carr R, Brocklehurst P, Doré CJ, et al, "Granulocyte-Macrophage Colony Stimulating Factor Administered as Prophylaxis for Reduction of Sepsis in Extremely Preterm, Small for Gestational Age Neonates (the PROGRAMS Trial): A Single-Blind, Multicentre, Randomised Controlled Trial," <i>Lancet</i>, 2009, 373(9659):226-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sargramostim-pediatric-drug-information/abstract-text/19150703/pubmed" id="19150703" target="_blank">19150703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10103305">
<a name="10103305"></a>Carr R, Modi N, Dore CJ, et al, “A Randomized, Controlled Trial of Prophylactic Granulocyte-Macrophage Colony-Stimulating Factor in Human Newborns Less Than 32 Weeks Gestation,” <i>Pediatrics</i>, 1999, 103(4 Pt 1):796-802.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sargramostim-pediatric-drug-information/abstract-text/10103305/pubmed" id="10103305" target="_blank">10103305</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sargramostim-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Danyelza (naxitamab) [prescribing information]. New York, NY: Y-mAbs Therapeutics Inc; November 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21205990">
<a name="21205990"></a>Freifeld AG, Bow EJ, Sepkowitz KA, et al; Infectious Disease Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2011;52(4):427-431.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sargramostim-pediatric-drug-information/abstract-text/21205990/pubmed" id="21205990" target="_blank">21205990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19047298">
<a name="19047298"></a>Gilman AL, Ozkaynak MF, Matthay KK, et al. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group. <i>J Clin Oncol</i>. 2009;27(1):85-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sargramostim-pediatric-drug-information/abstract-text/19047298/pubmed" id="19047298" target="_blank">19047298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sargramostim-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kushner.2019">
<a name="Kushner.2019"></a>Kushner BH, Modak S, Basu EM, Roberts SS, Cheung NV. High-dose naxitamab plus stepped-up dosing of GM-CSF for high-risk neuroblastoma (HR-NB): efficacy against histologically-evident primary refractory metastases in bone marrow (BM). <i>J Clin Oncol.</i> 2019;37(15)(suppl):10024 doi:10.1200/JCO.2019.37.15_suppl.10024</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-leukine.1">
<a name="leukine.1"></a>Leukine (sargramostim) [prescribing information]. Lexington, MA: Partner Therapeutics; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1375975">
<a name="1375975"></a>Lieschke GJ and Burgess AW, “Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor,” (1) <i>N Engl J Med</i>, 1992, 327(1):28-35.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sargramostim-pediatric-drug-information/abstract-text/1375975/pubmed" id="1375975" target="_blank">1375975</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1376442">
<a name="1376442"></a>Lieschke GJ and Burgess AW, “Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor,” (2) <i>N Engl J Med</i>, 1992, 327(2):99-106.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sargramostim-pediatric-drug-information/abstract-text/1376442/pubmed" id="1376442" target="_blank">1376442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22542709">
<a name="22542709"></a>Marlow N, Morris T, Brocklehurst P, et al. A randomised trial of granulocyte-macrophage colony-stimulating factor for neonatal sepsis: outcomes at 2 years. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2013;98:46-53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sargramostim-pediatric-drug-information/abstract-text/22542709/pubmed" id="22542709" target="_blank">22542709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12398579">
<a name="12398579"></a>Mayer D and Bednarczyk EM, “Interaction of Colony-Stimulating Factors and Fluorodeoxyglucose F<sup>18</sup> Positron Emission Tomography,” <i>Ann Pharmacother</i>, 2002, 36(11):1796-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sargramostim-pediatric-drug-information/abstract-text/12398579/pubmed" id="12398579" target="_blank">12398579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mora.2020">
<a name="Mora.2020"></a>Mora J, Chan GC, Morgenstern DA, et al. Naxitamab, a new generation anti-GD2 monoclonal antibody (mAb) for treatment of relapsed/refractory high-risk neuroblastoma (HR-NB). <i>J Clin Oncol</i>. 2020;38(15)(suppl):10543. doi:10.1200/JCO.2020.38.15_suppl.10543</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1903847">
<a name="1903847"></a>Nemunaitis J, Rabinowe SN, Singer JW, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. <i>NEJM</i>. 1991;324:1773-1778.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sargramostim-pediatric-drug-information/abstract-text/1903847/pubmed" id="1903847" target="_blank">1903847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11032599">
<a name="11032599"></a>Ozer H, Armitage JO, Bennett CL, et al, “2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines. American Society of Clinical Oncology Growth Factors Expert Panel,” <i>J Clin Oncol</i>, 2000, 18(20):3558-85.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sargramostim-pediatric-drug-information/abstract-text/11032599/pubmed" id="11032599" target="_blank">11032599</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26169616">
<a name="26169616"></a>Smith TJ, Bohlke K, Lyman GH, et al; American Society of Clinical Oncology. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>J Clin Oncol</i>. 2015;33(28):3199-3212.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sargramostim-pediatric-drug-information/abstract-text/26169616/pubmed" id="26169616" target="_blank">26169616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7562431">
<a name="7562431"></a>Stute N, Furman WL, Schell M, et al, “Pharmacokinetics of Recombinant Human Granulocyte - Macrophage Colony - Stimulating Factor in Children After Intravenous and Subcutaneous Administration,” <i>J Pharm Sci</i>, 1995, 84(7):824-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sargramostim-pediatric-drug-information/abstract-text/7562431/pubmed" id="7562431" target="_blank">7562431</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11272605">
<a name="11272605"></a>Trigg ME, Peters C, Zimmerman MB. Administration of recombinant human granulocyte-macrophage colony-stimulating factor to children undergoing allogeneic marrow transplantation; a prospective, randomized, double-masked, placebo-controlled trial. <i>Pediatr Transplantation</i>. 2000; 4:123-131.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sargramostim-pediatric-drug-information/abstract-text/11272605/pubmed" id="11272605" target="_blank">11272605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1554007">
<a name="1554007"></a>Trissel LA, Bready BB, Kwan JW, et al, “Visual Compatibility of Sargramostim With Selected Antineoplastic Agents, Anti-infectives, or Other Drugs During Simulated Y-Site Injection,” <i>Am J Hosp Pharm</i>, 1992, 49(2):402-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sargramostim-pediatric-drug-information/abstract-text/1554007/pubmed" id="1554007" target="_blank">1554007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15197022">
<a name="15197022"></a>Waselenko JK, MacVittie TJ, Blakely WF, et al, "Medical Management of the Acute Radiation Syndrome: Recommendations of the Strategic National Stockpile Radiation Working Group," <i>Ann Intern Med</i>, 2004, 140(12):1037-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sargramostim-pediatric-drug-information/abstract-text/15197022/pubmed" id="15197022" target="_blank">15197022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20879881">
<a name="20879881"></a>Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. <i>N Engl J Med.</i> 2010;363(14):1324-1334.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sargramostim-pediatric-drug-information/abstract-text/20879881/pubmed" id="20879881" target="_blank">20879881</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12781 Version 160.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
